In our analysis, most patients had FGFR3-TACC3 fusions (n = 9; 8 patients with GBM, 1 patient with PLNTY), with the remaining patients exhibiting FGFR1 mutations (K656E, n = 2, 1 patient with GBM, 1 patient with diffuse astrocytoma grade 2; N546K, n = 1, patient had other glioma) and an FGFR1-MITF fusion (n = 1, patient had GBM). Here, FGFR1 is linked to central nervous system cancer.